Le Lézard
Classified in: Health
Subject: SVY

Injectable Drug Delivery: A 2-Day Seminar Presented by Experts (London, UK - March 18-19, 2020)


DUBLIN, Jan. 27, 2020 /PRNewswire/ -- The "Injectable Drug Delivery" conference has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

This seminar has been designed to provide all those working in the industry with the latest information on the next generation of injectable drugs and devices and an update on recent trends, technologies and applications. It will also be a great opportunity to meet industry leaders, as well as like-minded professionals, and share common experience and best practice.

Attending this two-day seminar, presented by experts in the field, will:

Injectable drug delivery is considered to be one of the most effective routes of administration due to the speed and effectiveness of delivery to the target, and recent developments have improved the patient experience.

The global injectable drug delivery market continues to grow and technology is advancing. This, coupled with the ever-changing regulatory requirements, means that it is imperative for companies to stay abreast of the latest developments and challenges within the industry in order to remain compliant, as well as gaining a competitive edge.

Agenda

Programme Day One

Devices, technology, and latest trends

Latest developments for injectable drug delivery solutions

Recent advances in large-volume injection

Discussion session

Developments in technology with injectables - digitalisation and smart technology

Digital design in the development of injectable systems

Discussion session

Case study: Connected needle-free technology

Patient considerations and design processes

Assessing injection site pain

Discussion session

Betwixt and between - managing the interface between PFS and autoinjector

Interactive panel discussion: Next-generation innovations in drug delivery
Moderator: Dr Gregory Berman
Panellists: Ian Thompson, Neil Williams, Markus Bauss, Dr Thomas Schoenknecht

Drinks reception

Programme Day Two

Regulatory update and human factors

The EU regulatory framework for injectable delivery systems

Human factors validation - when is usability testing not required?

Discussion session

Sustainability - its impact on self-care drug delivery

Packaging and quality

Extractables and leachables (E&L) in injectable drug products

Discussion session

Pre-filled syringes in a nutshell

The relationship between the ICH guidelines for impurities and E&L thresholds

Interactive panel discussion: The future with smart injection devices
Moderator: Dr Gregory Berman
Panellists: Ian Thompson and Dr Thomas Schoenknecht

Chair's closing remarks

For more information about this conference visit https://www.researchandmarkets.com/r/umvzr6

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...

at 17:15
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...

at 17:05
Sirona Biochem Corp. ("Sirona") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in...

at 17:00
The Doctors Company, the nation's largest physician-owned medical malpractice insurer, announced today that it has approved a 2024 premium dividend of approximately $14.7 million, bringing the total of declared dividends to date to $470 million....

at 17:00
Northern Virginia Oral, Maxillofacial & Implant Surgery ("NOVA OMS") has learned of a data security incident that may have impacted data belonging to certain patients and guarantors. On October 5, 2023, NOVA OMS became aware of unusual activity on...

at 17:00
The Journey Venture Studio announced today a strategic collaboration with Valleywise Health, a comprehensive healthcare system with locations throughout the Phoenix metro area. In pursuit of fostering innovation, this collaboration is set to...



News published on and distributed by: